Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease predominantly affecting diarthroidal joints. Following the successful application of biologic agents, several small molecule inhibitors are currently under clinical trials. Small molecule inhibitors have several strengths compared with biologics. First, they can target several inflammatory cytokines together by blocking common signal transduction pathways. Second, they can be taken orally. Third, the price can be made flexible. Among the several small molecule inhibitors in the development process, fostamatinib and tofacitinib are the closest to the clinics at the moment. Fostamatinib, which is a Syk inhibitor, showed superior efficacy over placebo with tolerable safety signals. Diarrhea, hypertension and infection are representative adverse events. Tofacitinib, which is JAK inhibitor, is now finishing phase 3 clinical trials. It showed clinical efficacy comparable to Adalimumab and similar adverse effect profiles to the biologics, which include opportunistic infections. For laboratory abnormalities, leukopenia, anemia, increase of LDL and serum Cr were reported, which, however, were stabilized with prolonged use. Other classes of small molecule inhibitors did not show impressive efficacy as these small molecule inhibitors. In conclusion, small molecule inhibitors are promising novel therapeutic agents for the treatment of RA. They will be able to change the treatment paradigm of RA if they can show long-term safety. Key Words. Rheumatoid arthritis, Small molecule inhibitor 서 론 류마티스관절염은 주로 활막 관절을 침범하는 원인불명 의 만성 전신 염증성 질환이다. 류마티스관절염의 원인은 아직 정확히 알려져 있지 않지만, 최근의 연구결과에 의하 면 서로 다른 종류의 다양한 염증성 사이토카인들이 발병 에 중요한 역할을 하는 것으로 알려졌다 (1). 최근 TNF-α 를 표적으로 하는 항 TNF-α 제제(Etanercept, Infliximab, Adalimumab, Golimumab, Certolizumab), IL-6를 표적으로 하는 항 IL-6 수용체 항체(tocilizumab) 등 생물학적 치료제 의 성공적인 도입은 류마티스관절염의 새로운 치료전략을 제시해 주고 있다 (2-7). 하지만 류마티스관절염 치료에 있어서 최근의 급속한 발 전에도 불구하고, 류마티스관절염의 완치라는 목표는 여 전히 요원한 과제로 남아 있다. 가장 효과적인 생물학적 제제라고 하여도 ACR20에 도달하는 비율이 60% 내외에 머물고 있으며, ACR50, ACR70는 각각 40%, 20%에 머물
13 IR, incomplete response 
Tofacitinib
Tofacitinib은 Janus activated kinase (JAK) 분자를 선택적으 The values are 51.5% and 54.9% respectively at 6 months. IR, incomplete response; DMARD, disease modifying anti-rheumatic drugs 
